What TuHURA Biosciences, Inc. told the SEC could break it.

TuHURA received a Nasdaq notice for trading below the $1.00 minimum bid price for 30 consecutive days, with a 180-day cure period to July 28, 2026; failure to regain compliance risks delisting and reduced liquidity.

“e Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market, due to the bid price of the Company's common stock closing below the minimum $1 per share for the 30 consecutive business days prior to the date of the Notification Letter.”

TuHURA has no approved products or product revenue, incurred a $30.1M net loss in 2025, and funds operations through capital stock, warrants, convertible notes and an ATM program — needing continued financing for years before any potential commercialization of IFx/TBS-2025.

“We do not have any products approved for sale and have not generated any revenue from product sales. We have funded our operations primarily through the issuance of capital stock, warrants and convertible notes. We are not profitable and has incurred significant operating losses in each period since our inception, including net losses of $30.1 million for the year ended”

TuHURA's IFx-Hu2.0 and TBS-2025 candidates require lengthy, uncertain FDA approval, and future commercial economics are exposed to evolving drug-pricing, importation (e.g., Florida's Canadian-import program) and health-care-reform measures that could limit reimbursement.

“We expect that additional state and federal health care re”

TuHURA's cell-based therapy manufacturing depends on reagents, specialized equipment and specialty materials available only from sole-source or a limited number of vendors, so a supplier loss (regulatory, financial, labor or strategic) could impair its ability to manufacture and supply product candidates.

“For some of these reagents, equipment, and materials, we rely or may rely on sole source vendors or a limited number of vendors, which could impair our ability to manufacture and supply our products.”